Humacyte, INC Form 4 insider transactions

Director Susan Richards Windham-Bannister was granted 80,000 stock options in Humacyte, Inc. as part of a standard equity compensation arrangement.

Director Michael T. Constantino was granted 80,000 stock options in Humacyte, Inc. as part of a standard equity compensation plan.

Director Max N. Wallace was granted 80,000 stock options in Humacyte, Inc. with an exercise price of $1.08.

Humacyte CEO Laura E. Niklason reported a grant of 80,000 stock options to her spouse.

Director Kathleen Sebelius was granted 80,000 stock options in Humacyte, Inc. as part of a standard equity compensation plan.

Director Keith Anthony Jones was granted 80,000 stock options in Humacyte, Inc. as part of a standard equity compensation plan.

Director Charles Bruce Green was granted 80,000 stock options in Humacyte, Inc. as part of a standard equity compensation plan.

Director Diane Seimetz was granted 80,000 stock options in Humacyte, Inc. as part of a standard equity compensation arrangement.

Director John Philip Bamforth was granted 80,000 stock options in Humacyte, Inc. as part of a standard equity compensation plan.

Director Emery N. Brown was granted 80,000 stock options in Humacyte, Inc. with an exercise price of $1.08.

Humacyte, Inc. director Brady W. Dougan was granted 80,000 stock options with an exercise price of $1.08 per share.

Director Kathleen Sebelius reported a transaction involving Humacyte, Inc. common stock on May 19, 2026.

Humacyte, Inc. reports a Form 4 filing detailing a stock purchase by Director Michael T. Constantino.

Humacyte's CFO and Chief Corp. Dev. Off., Dale A. Sander, sold 45,887 shares of common stock for $0.8967 each to cover tax withholding obligations related to vested restricted stock units.

Humacyte's Chief Medical Officer, Shamik J. Parikh, sold 45,887 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Fresenius Medical Care Holdings Inc. reports it is no longer a 10% owner of Humacyte, Inc. due to an increase in outstanding shares, not through asset disposition.

Humacyte, Inc.'s CFO and Chief Corporate Development Officer, Dale A. Sander, was granted 311,100 restricted stock units, vesting in two tranches through May 2027.

Humacyte's Chief Medical Officer, Shamik J. Parikh, was granted 311,100 restricted stock units, vesting in two tranches in 2026 and 2027.

Humacyte Director Brady W. Dougan was granted 311,100 stock options with a $1.23 exercise price, vesting over three years.

Humacyte's President and CEO, Laura E. Niklason, was granted 311,100 stock options with an exercise price of $1.23, vesting over three years.

Humacyte Director Brady W. Dougan sold over 2.2 million shares of common stock through an entity he controls, Ayabudge LLC, across three transactions in mid-August 2025.

An entity indirectly associated with Humacyte's CEO, Laura E. Niklason, sold over 2.24 million shares of common stock in mid-August 2025 under a pre-arranged plan.

Humacyte, Inc. Director Todd Pope was granted 80,000 stock options with an exercise price of $2.41, vesting over four years.

Humacyte, Inc. Director Emery N. Brown was granted 80,000 stock options with an exercise price of $2.41, vesting over four years.

Humacyte, Inc. has reported that Director Keith Anthony Jones was granted 80,000 stock options with an exercise price of $2.41 per share, vesting over four years.

Humacyte, Inc. Director Max N. Wallace was granted 80,000 stock options with an exercise price of $2.41, vesting over four years.

Humacyte, Inc. Director Susan Richards Windham-Bannister was granted 80,000 stock options with an exercise price of $2.41, vesting over four years.

Humacyte, Inc. CEO Laura E. Niklason filed an SEC Form 4 detailing the acquisition of 80,000 stock options and amending a previous filing to correct beneficial ownership information.

Humacyte, Inc. Director and 10% Owner Brady W. Dougan has filed an amended Form 4 with the SEC to correct a previous reporting error regarding the sale of 510,161 shares of common stock.

Humacyte, Inc. Director Charles Bruce Green was granted 80,000 stock options with an exercise price of $2.41, vesting over four years.